|
1
|
Clark JC, Dass CR and Choong PF: A review
of clinical and molecular prognostic factors in osteosarcoma. J
Cancer Res Clin Oncol. 134:281–297. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Davicioni E, Wai DH and Anderson MJ:
Diagnostic and prognostic sarcoma signatures. Mol Diagn Ther.
12:359–374. 2008. View Article : Google Scholar
|
|
3
|
Fagioli F, Biasin E, Mereuta OM, et al:
Poor prognosis osteosarcoma: new therapeutic approach. Bone Marrow
Transplant. 41(Suppl 2): S131–S134. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sakamoto A and Iwamoto Y: Current status
and perspectives regarding the treatment of osteo-sarcoma:
chemotherapy. Rev Recent Clin Trials. 3:228–231. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang LL: Biology of osteogenic sarcoma.
Cancer J. 11:294–305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Federman N, Bernthal N, Eilber FC and Tap
WD: The multi-disciplinary management of osteosarcoma. Curr Treat
Options Oncol. 10:82–93. 2009. View Article : Google Scholar
|
|
7
|
Hakuma N, Betsuyaku T, Kinoshita I, et al:
High incidence of extracellular matrix metalloproteinase inducer
expression in non-small cell lung cancers. Association with
clinicopathological parameters. Oncology. 72:197–204. 2007.
View Article : Google Scholar
|
|
8
|
Jia L, Wei W, Cao J, Xu H, Miao X and
Zhang J: Silencing CD147 inhibits tumor progression and increases
chemosensitivity in murine lymphoid neoplasm P388D1 cells. Ann
Hematol. 88:753–760. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Aratake Y, Marutsuka K, Kiyoyama K, et al:
EMMPRIN (CD147) expression and differentiation of papillary thyroid
carcinoma: implications for immunocytochemistry in FNA cytology.
Cytopathology. 21:103–110. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen T and Zhu J: Evaluation of EMMPRIN
and MMP-2 in the prognosis of primary cutaneous malignant melanoma.
Med Oncol. 27:1185–1191. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang C, Tu Z, Du S, Wang Y and Wang Q:
Expression of matrix metalloproteinase 2 and extracellular matrix
metalloproteinase inducer are unfavorable postoperative prognostic
factors in intrahepatic cholangiocarcinoma. Pathol Oncol Res.
16:47–53. 2010. View Article : Google Scholar
|
|
12
|
Buergy D, Fuchs T, Kambakamba P, et al:
Prognostic impact of extracellular matrix metalloprotease inducer:
immunohistochemical analyses of colorectal tumors and
immunocytochemical screening of disseminated tumor cells in bone
marrow from patients with gastrointestinal cancer. Cancer.
115:4667–4678. 2009. View Article : Google Scholar
|
|
13
|
Liang YX, He HC, Han ZD, et al: CD147 and
VEGF expression in advanced renal cell carcinoma and their
prognostic value. Cancer Invest. 27:788–793. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Han ZD, Bi XC, Qin WJ, et al: CD147
expression indicates unfavourable prognosis in prostate cancer.
Pathol Oncol Res. 15:369–374. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ju XZ, Yang JM, Zhou XY, Li ZT and Wu XH:
EMMPRIN expression as a prognostic factor in radiotherapy of
cervical cancer. Clin Cancer Res. 14:494–501. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sillanpaa S, Anttila M, Suhonen K, et al:
Prognostic significance of extracellular matrix metalloproteinase
inducer and matrix metalloproteinase 2 in epithelial ovarian
cancer. Tumour Biol. 28:280–289. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang JM, O’Neill P, Jin W, et al:
Extracellular matrix metalloproteinase inducer (CD147) confers
resistance of breast cancer cells to anoikis through inhibition of
Bim. J Biol Chem. 281:9719–9727. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu H, Evans B, O’Neill P, et al: A role
for p53 in the regulation of extracellular matrix metalloproteinase
inducer in human cancer cells. Cancer Biol Ther. 8:1722–1728. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bougatef F, Quemener C, Kellouche S, et
al: EMMPRIN promotes angiogenesis through hypoxia-inducible
factor-2alpha-mediated regulation of soluble VEGF isoforms and
their receptor VEGFR-2. Blood. 114:5547–5556. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tang Y, Nakada MT, Kesavan P, et al:
Extracellular matrix metalloproteinase inducer stimulates tumor
angiogenesis by elevating vascular endothelial cell growth factor
and matrix metalloproteinases. Cancer Res. 65:3193–3199. 2005.
|
|
21
|
Zheng HC, Takahashi H, Murai Y, et al:
Upregulated EMMPRIN/CD147 might contribute to growth and
angiogenesis of gastric carcinoma: a good marker for local invasion
and prognosis. Br J Cancer. 95:1371–1378. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Duivenvoorden WC, Hirte HW and Singh G:
Transforming growth factor beta1 acts as an inducer of matrix
metalloproteinase expression and activity in human
bone-metastasizing cancer cells. Clin Exp Metastasis. 17:27–34.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Quemener C, Gabison EE, Naimi B, et al:
Extracellular matrix metalloproteinase inducer up-regulates the
urokinase-type plasminogen activator system promoting tumor cell
invasion. Cancer Res. 67:9–15. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Riethdorf S, Reimers N, Assmann V, et al:
High incidence of EMMPRIN expression in human tumors. Int J Cancer.
119:1800–1810. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang P, Xu TY, Guan YF, Su DF, Fan GR and
Miao CY: Perivascular adipose tissue-derived visfatin is a vascular
smooth muscle cell growth factor: role of nicotinamide
mononucleotide. Cardiovasc Res. 81:370–380. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang P, Xu TY, Guan YF, et al:
Nicotinamide phosphoribosyltransferase protects against ischemic
stroke through SIRT1-dependent adenosine monophosphate-activated
kinase pathway. Ann Neurol. 69:360–374. 2011. View Article : Google Scholar
|
|
27
|
Wang P, Guan YF, Du H, Zhai QW, Su DF and
Miao CY: Induction of autophagy contributes to the neuroprotection
of nicotinamide phosphoribosyltransferase in cerebral ischemia.
Autophagy. 8:77–87. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang P, Zhang RY, Song J, et al: Loss of
AMP-activated protein kinase-alpha2 impairs the insulin-sensitizing
effect of calorie restriction in skeletal muscle. Diabetes.
61:1051–1061. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Enneking WF, Spanier SS and Goodman MA: A
system for the surgical staging of musculoskeletal sarcoma. Clin
Orthop Relat Res. 153:106–120. 1980.PubMed/NCBI
|
|
30
|
Enneking WF, Spanier SS and Goodman MA:
Current concepts review. The surgical staging of musculoskeletal
sarcoma. J Bone Joint Surg Am. 62:1027–1030. 1980.PubMed/NCBI
|
|
31
|
Picci P, Bacci G, Campanacci M, et al:
Histologic evaluation of necrosis in osteosarcoma induced by
chemotherapy. Regional mapping of viable and nonviable tumor.
Cancer. 56:1515–1521. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang P, Yang FJ, Du H, et al: Involvement
of leptin receptor long isoform (LepRb)-STAT3 signaling pathway in
brain fat mass- and obesity-associated (FTO) downregulation during
energy restriction. Mol Med. 17:523–532. 2011.PubMed/NCBI
|
|
33
|
Zhou Q, Zhu Y, Deng Z, Long H, Zhang S and
Chen X: VEGF and EMMPRIN expression correlates with survival of
patients with osteosarcoma. Surg Oncol. 20:13–19. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Madigan MC, Kingsley EA, Cozzi PJ,
Delprado WJ, Russell PJ and Li Y: The role of extracellular matrix
metalloproteinase inducer protein in prostate cancer progression.
Cancer Immunol Immunother. 57:1367–1379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ishibashi Y, Matsumoto T, Niwa M, et al:
CD147 and matrix metalloproteinase-2 protein expression as
significant prognostic factors in esophageal squamous cell
carcinoma. Cancer. 101:1994–2000. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nabeshima K, Iwasaki H, Koga K, Hojo H,
Suzumiya J and Kikuchi M: Emmprin (basigin/CD147): matrix
metalloproteinase modulator and multifunctional cell recognition
molecule that plays a critical role in cancer progression. Pathol
Int. 56:359–367. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cheng MF, Tzao C, Tsai WC, et al:
Expression of EMMPRIN and matriptase in esophageal squamous cell
carcinoma: correlation with clinicopathological parameters. Dis
Esophagus. 19:482–486. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dean NR, Newman JR, Helman EE, et al:
Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of
head and neck cancer. Clin Cancer Res. 15:4058–4065. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kuang YH, Chen X, Su J, et al: RNA
interference targeting the CD147 induces apoptosis of multi-drug
resistant cancer cells related to XIAP depletion. Cancer Lett.
276:189–195. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Han ZD, He HC, Bi XC, et al: Expression
and clinical significance of CD147 in genitourinary carcinomas. J
Surg Res. 160:260–267. 2010. View Article : Google Scholar : PubMed/NCBI
|
